Testosterone Enanthate and Anesthesia: Perioperative Interaction Guide

Testosterone enanthate (TE) is a long-acting injectable testosterone ester, marketed as Delatestryl and in generic form, used in FDA-approved testosterone replacement therapy for men with confirmed hypogonadism and prescribed off-label in some gender-affirming and performance contexts. It is dosed by intramuscular injection, typically every one to two weeks, and has an elimination half-life of roughly 4.5 days, so a single skipped dose does not clear the drug quickly.

The core, quotable answer: testosterone enanthate is FDA-labeled with a warning about venous thromboembolic events and a caution about monitoring prothrombin time when the drug is started or stopped in patients on anticoagulants; that labeling is the strongest available anchor for perioperative risk counseling. The size of the VTE risk increase attributable to testosterone therapy specifically in the surgical window has not been established in a large randomized trial and should not be quoted as a precise number without checking the current primary literature. Practically, the decision that matters is whether hematocrit, anticoagulant status, and procedure complexity together push a given patient into a higher-risk tier, not whether they use testosterone at all.

What is actually established, and what is not

Reader intent here usually comes down to one question: "can I still have surgery on TE, and does anyone need to be told anything special?" The honest answer has three tiers of certainty.

Established: Testosterone therapy, including TE, raises hematocrit in a dose- and duration-dependent way, an effect seen consistently across trials of testosterone replacement. The FDA-approved labeling for testosterone products carries a warning about venous thromboembolic events (deep vein thrombosis and pulmonary embolism) and instructs that prothrombin time be monitored when testosterone therapy is started or stopped in patients also taking anticoagulants such as warfarin (per FDA-approved product labeling; check the current label for the exact wording before citing it verbatim, since labels are revised over time).

Plausible but not proven in this specific setting: Mechanistic and animal data suggest androgens can alter platelet thromboxane receptor density and cardiac repolarization currents, which could theoretically affect hemodynamic response to volatile anesthetics or bleeding tendency. No controlled human trial has tested these effects specifically in surgical patients on TE.

Not established: The exact magnitude of added VTE risk from TE during the surgical window, the optimal duration to hold TE before a given procedure type, and whether holding TE before surgery meaningfully changes outcomes compared with proceeding with standard VTE prophylaxis. These gaps mean guidance in this space is largely extrapolated from general perioperative VTE management and observational testosterone-safety data, not from a purpose-built surgical trial in TE users.

Should you stop testosterone enanthate before surgery?

For most elective, shorter, low-bleeding-risk procedures, disclosure without automatic discontinuation is the common approach: tell the surgical and anesthesia teams you are on TE, get a current hematocrit, and let the team decide based on that value and the procedure type. There is no evidence that briefly continuing TE through a routine outpatient procedure with normal labs causes harm, but there is also no trial confirming it is risk-free.

For major or prolonged surgery (large orthopedic procedures, major abdominal surgery, anything with an expected general anesthesia time over roughly two hours), many perioperative teams take a more cautious approach: checking hematocrit and coagulation status well before the date, and considering a temporary hold of TE for a period tied to its half-life if hematocrit or other risk factors are elevated. Because full clearance of TE takes roughly two to three weeks, a "hold" only meaningfully reduces circulating drug if it starts well in advance of surgery. No randomized trial has established that holding TE for a specific number of days reduces perioperative VTE events; this remains a matter of clinical judgment applied to the general principles of VTE risk reduction.

Emergency surgery cannot wait for any of this. The priority is telling the anesthesia team immediately so they can order a stat hematocrit and coagulation panel, plan intraoperative VTE prophylaxis, and watch hemodynamics closely at induction if erythrocytosis is confirmed.

How testosterone enanthate interacts with specific anesthesia-related drugs

Volatile anesthetics. Volatile agents cause dose-dependent vasodilation and hypotension. A patient with TE-related erythrocytosis who is also relatively volume-contracted, a pattern sometimes seen with elevated hematocrit, may show a more pronounced blood pressure drop at induction. Animal and basic-science data suggest androgens can affect cardiac repolarization currents, which is a reason to note baseline ECG findings in long-term, higher-dose TE users, but this has not been shown to produce a clinically significant QT effect under volatile anesthesia in controlled human studies.

Warfarin and other oral anticoagulants. This is the best-documented interaction. Testosterone is understood to affect hepatic warfarin metabolism, and product labeling instructs that prothrombin time be monitored when testosterone therapy starts or stops in a patient on anticoagulants. Practically, a patient bridged with heparin or warfarin around surgery who is also on TE needs closer INR monitoring, since testosterone can shift INR in either direction around the time therapy is initiated, stopped, or dose-adjusted. Anyone managing anticoagulation for this patient should be told about TE use explicitly, not left to infer it from a medication list.

Opioids. There is no controlled human evidence that testosterone at replacement or typical TRT doses changes opioid dose requirements. Anesthesiologists do not routinely adjust opioid dosing for TE use alone.

Neuromuscular blocking agents. No documented pharmacokinetic interaction exists between TE and agents such as succinylcholine, rocuronium, or vecuronium. Standard train-of-four monitoring is appropriate; there is no basis to modify NMBA dosing for TE use by itself.

What labs should be checked before surgery

• Complete blood count, with hematocrit and hemoglobin as the values most relevant to perioperative risk. A markedly elevated hematocrit is a recognized reason some anesthesiologists request delaying an elective procedure, though the exact cutoff used varies by institution and should be confirmed locally rather than treated as a universal number.
• Coagulation panel (PT/INR), essential for anyone co-prescribed warfarin, and reasonable as a baseline even without anticoagulant use given testosterone's pro-coagulant tendency.
• Hepatic function panel, since injectable TE carries a lower hepatotoxic burden than oral androgens but can still contribute to transaminase elevation, which matters because most anesthetic agents undergo hepatic metabolism.
• Trough serum testosterone, drawn just before the next scheduled injection, to confirm whether levels are in a physiologic replacement range or supraphysiologic, since higher troughs are associated with higher hematocrit.

Restarting testosterone enanthate after surgery

There is no guideline-level, trial-tested restart protocol specific to TE after surgery. The general principles clinicians apply are confirmed hemostasis (no active bleeding), return of ambulation to reduce stasis-related VTE risk, and resolution of any perioperative anticoagulation that was affecting INR. For minor outpatient procedures, resuming at the next scheduled injection is commonly accepted once bleeding risk has passed. For major surgery, some hormone clinics favor a longer pause, on the order of several weeks, with a repeat hematocrit before the first postoperative injection, but this is institutional practice rather than an evidence-based standard, and the surgeon and prescribing clinician should agree on timing together.

Alcohol around the time of surgery

Alcohol is not a formal pharmacologic contraindication to TE in ordinary use. Around surgery, though, alcohol prolongs bleeding time by inhibiting platelet aggregation, which sits awkwardly next to TE's pro-coagulant tendency: alcohol raises intraoperative bleeding risk while TE raises postoperative clotting risk, and combining both makes hemostasis management less predictable. Standard pre-op alcohol abstinence, typically at least 48 hours, applies to TE users the same as anyone else. Heavy, chronic alcohol use combined with TE has also been linked to mild transaminase elevation in case reports, which can complicate pre-op liver panel results and delay clearance.

What to tell your surgical and anesthesia teams

• The formulation, dose, and injection frequency of your testosterone (for example, testosterone enanthate 200 mg/mL every two weeks).
• The date of your last injection.
• Any concurrent anticoagulant or antiplatelet medication, especially warfarin, clopidogrel, or a direct oral anticoagulant.
• Your most recent hematocrit value and when it was drawn.
• Any personal or first-degree family history of DVT, pulmonary embolism, or a known clotting disorder.

Pre-anesthesia evaluation practice in the United States calls for complete disclosure of hormonal therapies as part of standard risk stratification; this is a matter of routine anesthesia practice rather than a TE-specific rule, and it applies the same way it would to any hormone or supplement that affects clotting or hemodynamics.

Higher-risk situations that deserve extra attention

Age over 65. A large randomized cardiovascular safety trial of testosterone therapy in men aged 45 to 80 with hypogonadism and cardiovascular risk factors (the TRAVERSE trial, published in the New England Journal of Medicine, 2023) did not find an increase in major adverse cardiovascular events with testosterone use, but reported a numerically higher rate of venous thromboembolism in the testosterone group. The exact rates and statistical comparison should be confirmed against the published trial before being quoted, since this summary is describing the trial's general finding rather than reproducing its precise figures. For an older surgical patient on TE, this is a reason to plan explicit VTE prophylaxis rather than to avoid surgery.

Polycythemia vera or hereditary thrombophilia. TE is generally considered inappropriate in patients with pre-existing polycythemia vera. Patients with known thrombophilias such as factor V Leiden or protein C or S deficiency face compounded risk when TE and surgical stress overlap, and a hematology consultation before elective surgery is reasonable.

Concurrent erythropoiesis-stimulating agents. Combining an ESA (such as epoetin alfa) with TE produces an erythropoietic stimulus that is more than the sum of either alone. An elevated hematocrit in this combination is a reason to consider phlebotomy in addition to holding the injection.

Evidence-status interaction assessment

Use this table to sort perioperative claims about TE by how solid the underlying evidence actually is, and what still needs to be checked before it goes into a chart note or patient counseling script.

Common questions

Evidence boundary

What is established: testosterone enanthate elevates hematocrit, manufacturer labeling cautions against venous thromboembolic events, and labeling requires prothrombin time monitoring when therapy is modified in anticoagulated patients. What is plausible but unproven: effects on hemodynamic response to volatile anesthetics and cardiac repolarization, supported by mechanistic reasoning and animal data but lacking controlled human surgical evidence. What is not established: the exact degree of increased surgical VTE risk attributable to testosterone enanthate, or the ideal timing and necessity of pre-operative discontinuation for any individual patient. This article does not offer individualized dosing or pre-operative hold recommendations; the surgical team and prescribing physician should make these determinations based on the patient's laboratory values and procedure-specific risk factors. Patients experiencing chest pain, dyspnea, leg edema, or calf pain in the postoperative period should obtain urgent medical assessment rather than delaying until a scheduled follow-up visit.